An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma

Published:2023-05 Issue:5 Volume:41 Page:919-932.e5
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Chen Yan-Xing,Wang Zi-Xian,Jin Ying,Zhao Qi,Liu Ze-Xian,Zuo Zhi-Xiang,Ju Huai-Qiang,Cui Chengxu,Yao Jun,Zhang Yanqiao,Li Mengxia,Feng Jifeng,Tian Lin,Xia Xiao-Jun,Feng Hui,Yao Sheng,Wang Feng-Hua,Li Yu-Hong,Wang Feng,Xu Rui-Hua^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference80 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J. Clin.,2021

2. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020;Qiu;Cancer Commun.,2021

3. Global burden of oesophageal and gastric cancer by histology and subsite in 2018;Arnold;Gut,2020

4. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer;Bleiberg;Eur. J. Cancer,1997

5. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer;Liu;Am. J. Cancer Res.,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells;Frontiers in Immunology;2024-07-15

2. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure;ESMO Open;2024-07

3. The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma;Cancer Letters;2024-07

4. Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study;British Journal of Cancer;2024-06-27

5. Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma;Anti-Cancer Drugs;2024-03-22